Drug intelligence / Profile preview

Captisol-enabled iohexol

Development stage: Unknown
Lead developer: Ligand Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Captisol-enabled iohexol (CE-Iohexol) is a next-generation iodinated contrast agent developed by Ligand Pharmaceuticals to improve the safety profile of diagnostic imaging. It consists of the standard contrast agent iohexol formulated with Captisol (sulfobutylether-β-cyclodextrin), a chemically modified cyclodextrin excipient. This formulation is specifically designed to mitigate the risk of contrast-induced acute kidney injury (CI-AKI), a common complication in patients with renal impairment undergoing procedures like CT scans or cardiac interventions. Preclinical data indicated a significant reduction in nephrotoxicity compared to standard iohexol, and Phase 1 clinical trials have demonstrated pharmacokinetic bioequivalence to the reference product Omnipaque.

Other names: iohexol + sulfobutylether-beta-cyclodextrin

Beyond the preview

Go deeper on Captisol-enabled iohexol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Captisol-enabled iohexol.

Explore the full profile